In a press briefing today at Pfizer’s headquarters in New York, New York, Pfizer’s executives reviewed their progress with biosimilars to date and underscored the need for a level playing field if biosimilars are to compete with brand-name biologics in the United States.
In a press briefing today at Pfizer’s headquarters in New York, New York, Pfizer’s executives reviewed their progress with biosimilars to date and underscored the need for a level playing field if biosimilars are to compete with brand-name biologics in the United States.
Richard Blackburn, global president for Europe, Africa, the Middle East, and biosimilars for Pfizer Essential Health, said that projections of biosimilars’ eventual share of the global biologics market could equate to about $40 billion per year in sales—a figure he called “too big to ignore.”
Blackburn added that sales of Pfizer’s biosimilar infliximab, Inflectra, grew by 66% last year, earning the company $420 million. Despite that that progress, and “notwithstanding our confidence and our optimism about the future…things won’t happen automatically” to spur biosimilar uptake in the United States. Blackburn warned that stakeholders will have to align on their priorities. There remains a need for education to help clear up “misinformation” about biosimilars, as well as a need for fair and equal market access.
There will also have to be a consensus about what constitutes reasonable pricing for a biosimilar product. “While pricing is at the heart of the biosimilars issues, and cost savings are kind of the point here,” he said, the same kinds of savings provided by generic drugs “will not be achievable” with biosimilars given the costs associated with development. “If that’s what stakeholders strive for, then we will find that companies are unable to make money, and we won’t see successive waves of new compounds coming to market over the next 20-odd years.”
As far as savings from Inflectra are concerned, Pfizer said that its second-quarter average sales price (ASP) for Inflectra is $650, an approximate 17% discount to Remicade’s $786 ASP. That’s progress from the approximate 13% discount in the first quarter of the year, and an approximate 10% discount in the final quarter of 2017. Discounts provided to hospitals and clinics for the drug are generally higher, in the range of 25% to 40%.
According to John Kennedy, general manager of US biosimilars for Pfizer Essential Health, in the last quarter of 2017, Inflectra had a 5.6% share of infliximab market by volume. About half of that share came from highly integrated systems, such as the United States Department of Veterans Affairs.
“In general, these highly integrated systems have been able to prioritize sustainable cost savings over short-term rebates,” said Kennedy.
However, outside these systems, Kennedy said, contracts struck between payers and the reference infliximab’s (Remicade) sponsor, Johnson & Johnson (J&J), have been creating hurdles for Inflectra in the marketplace. “Anticompetitive practices, like J&J’s exclusionary contracting, need to be stopped,” he said.
Blackburn added that “the extent to which we’ve seen exclusionary practices in the [United States] probably has been the thing that … we’ve had to deal with perhaps more than we anticipated.”
Pfizer has not yet seen the contracts used by J&J, Eric Aaronson, JD, senior vice president and chief counsel for Pfizer Essential Health, made clear, but Pfizer’s position on J&J’s contracting—as well as on its purported bundling of products—is informed by discussions with payers, and led to its lawsuit against the Remicade maker in 2017.
J&J has filed a motion to dismiss that lawsuit, and both parties are awaiting the court’s decision in the matter. However, according to Aaronson, the motion to dismiss did not deny any of Pfizer’s allegations. “Take whatever you want from that,” said Aaronson.
Looking to the future, Amrit Ray, MD, global president of research and development for Pfizer Essential Health, highlighted a pipeline of 7 late-stage biosimilar candidates, comprising adalimumab, trastuzumab, rituximab, bevacizumab, epoetin alfa, filgrastim, and pegfilgrastim, and said that Pfizer has 5 other proposed biosimilars in preclinical development.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.